Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

<p>Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retro...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Kazuhito Suzuki (22688384) (author)
Andere auteurs: Miku Ito (22688387) (author), Chika Sakai (5712761) (author), Hiroaki Tsuchiya (2437369) (author), David Bin-Chia Wu (7251623) (author), Yosuke Koroki (12979839) (author)
Gepubliceerd in: 2025
Onderwerpen:
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items